Table 5.
Multivariate analysis of variables correlated with clinical outcomes in the 180 patients with locoregionally advanced NPC.
| Endpoints | HR | 95%CI | P value |
|---|---|---|---|
| OS | |||
| Sex Male vs. Female |
1.284 | 0.515-3.200 | 0.591 |
| Age <45 vs. ≥45 |
1.081 | 0.455-2.571 | 0.860 |
| T category T3-4 vs. T1-2 |
0.798 | 0.282-2.259 | 0.671 |
| N category N0-1 vs. N2-3 |
1.615 | 0.554-4.707 | 0.380 |
| KPS <90 vs. ≥90 |
0.738 | 0.293-1.859 | 0.519 |
| Cisplatin regimen Weekly cisplatin vs. 3-weekly cisplatin |
0.547 | 0.225-1.333 | 0.184 |
| EBV DNA (copies/ml) <1000 vs. ≥1000 |
2.994 | 1.189-7.536 | 0.020 |
| DFS | |||
| Sex Male vs. Female |
0.950 | 0.382-2.360 | 0.912 |
| Age <45 vs. ≥45 |
0.649 | 0.267-1.574 | 0.339 |
| T category T3-4 vs. T1-2 |
0.527 | 0.183-1.515 | 0.234 |
| N category N0-1 vs. N2-3 |
1.345 | 0.441-4.102 | 0.603 |
| KPS <90 vs. ≥90 |
1.548 | 0.508-4.720 | 0.442 |
| Cisplatin regimen Weekly cisplatin vs. 3-weekly cisplatin |
0.507 | 0.199-1.291 | 0.155 |
| EBV DNA (copies/ml) <1000 vs. ≥1000 |
3.800 | 1.452-9.946 | 0.007 |
| LRRFS | |||
| Sex Male vs. Female |
0.607 | 0.149-2.463 | 0.484 |
| Age <45 vs. ≥45 |
1.443 | 0.339-6.133 | 0.620 |
| T category T3-4 vs. T1-2 |
0.150 | 0.015-1.471 | 0.103 |
| N category N0-1 vs. N2-3 |
0.145 | 0.013-1.565 | 0.112 |
| KPS <90 ≥90 |
0.431 | 0.096-1.939 | 0.273 |
| Cisplatin regimen Weekly cisplatin 3-weekly cisplatin |
0.341 | 0.071-1.628 | 0.177 |
| EBV DNA (copies/ml) <1000 ≥1000 |
15.653 | 1.765-138.780 | 0.013 |
| DMFS | |||
| Sex Male vs. Female |
1.442 | 0.439-4.736 | 0.547 |
| Age <45 vs. ≥45 |
0.368 | 0.113-1.196 | 0.096 |
| T category T3-4 vs. T1-2 |
0.589 | 0.189-1.837 | 0.362 |
| N category N0-1 vs. N2-3 |
3.827 | 0.768-19.066 | 0.101 |
| KPS <90 vs. ≥90 |
4.919 | 0.631-38.371 | 0.129 |
| Cisplatin regimen Weekly cisplatin vs. 3-weekly cisplatin |
0.399 | 0.124-1.285 | 0.124 |
| EBV DNA (copies/ml) <1000 vs. ≥1000 |
2.312 | 0.796-6.714 | 0.124 |
Abbreviations: CI, confidence interval; DFS, disease-free survival; DMFS, distant metastasis-free survival; HR, hazard ratio; IMRT, intensity-modulated radiotherapy; KPS, Karnofsky performance score; LRRFS, locoregional relapse-free survival; NPC, nasopharyngeal carcinoma; OS, overall survival.